Literature DB >> 21892714

MR-PET fusion imaging in evaluating adnexal lesions: a preliminary study.

V Fiaschetti1, F Calabria, S Crusco, A Meschini, F Nucera, O Schillaci, G Simonetti.   

Abstract

PURPOSE: The objective of this preliminary study was to examine the effects of combined magnetic resonance/positron emission tomography (MR-PET) evaluation in the morphofunctional characterisation of ovarian lesions.
MATERIALS AND METHODS: From June 2008 to September 2010, we evaluated 24 patients (mean age 44±10 years; range 24-74) with ovarian lesions incidentally detected on ultrasonography (US) and/or multislice computed tomography (CT). All patients underwent MR imaging of the pelvis and total-body CT-PET. PET and MR images were subsequently fused at postprocessing using specific anatomical criteria. Results were compared with the histological examination.
RESULTS: Of the 24 examined lesions, 19 were malignant and five were benign on histological examination. MR, CT-PET and MR-PET sensitivity was 84%, 74% and 94%, respectively and specificity 60%, 80% and 100%, respectively. Positive (PPV) and negative predictive (NPV) values were 93% and 44% for CT-PET, 89% and 50% for MR and 100% and 83% for MR-PET, respectively.
CONCLUSIONS: Pelvic MR-PET fusion imaging provides advantages in terms of sensitivity and especially specificity compared with MR imaging or CT-PET alone. The added value of this fusion imaging modality lies in combining the benefits of the morphological evaluation provided by MR imaging and the metabolic assessment provided by PET.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21892714     DOI: 10.1007/s11547-011-0720-7

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  18 in total

1.  Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer.

Authors:  Norbert Avril; Stefanie Sassen; Barbara Schmalfeldt; Joerg Naehrig; Stephan Rutke; Wolfgang A Weber; Martin Werner; Henner Graeff; Markus Schwaiger; Walther Kuhn
Journal:  J Clin Oncol       Date:  2005-09-12       Impact factor: 44.544

2.  Solitary pulmonary nodules: morphological and metabolic characterisation by FDG-PET-MDCT.

Authors:  A Orlacchio; O Schillaci; L Antonelli; S D'Urso; G Sergiacomi; P Nicolì; G Simonetti
Journal:  Radiol Med       Date:  2007-03-19       Impact factor: 3.469

3.  Complex adnexal masses: detection and characterization with MR imaging--multivariate analysis.

Authors:  H Hricak; M Chen; F V Coakley; K Kinkel; K K Yu; G Sica; P Bacchetti; C B Powell
Journal:  Radiology       Date:  2000-01       Impact factor: 11.105

Review 4.  Ovarian cancer.

Authors:  Nicoletta Colombo; Toon Van Gorp; Gabriella Parma; Frederic Amant; Gemma Gatta; Cristiana Sessa; Ignace Vergote
Journal:  Crit Rev Oncol Hematol       Date:  2006-10-02       Impact factor: 6.312

Review 5.  PET imaging in oncology.

Authors:  R Bar-Shalom; A Y Valdivia; M D Blaufox
Journal:  Semin Nucl Med       Date:  2000-07       Impact factor: 4.446

6.  Lymph node staging by positron emission tomography in patients with carcinoma of the cervix.

Authors:  P W Grigsby; B A Siegel; F Dehdashti
Journal:  J Clin Oncol       Date:  2001-09-01       Impact factor: 44.544

7.  The diagnostic accuracy of 18F-fluorodeoxyglucose PET/CT in patients with gynecological malignancies.

Authors:  Dan Grisaru; Benny Almog; Charles Levine; Ur Metser; Ami Fishman; Hedva Lerman; Joseph B Lessing; Einat Even-Sapir
Journal:  Gynecol Oncol       Date:  2004-09       Impact factor: 5.482

Review 8.  Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.

Authors:  Henry T Lynch; Murray Joseph Casey; Carrie L Snyder; Chhanda Bewtra; Jane F Lynch; Matthew Butts; Andrew K Godwin
Journal:  Mol Oncol       Date:  2009-02-21       Impact factor: 6.603

9.  The accurate staging of ovarian cancer using 3T magnetic resonance imaging--a realistic option.

Authors:  S J Booth; L W Turnbull; D R Poole; I Richmond
Journal:  BJOG       Date:  2008-06       Impact factor: 6.531

10.  Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET.

Authors:  Yoshihiro Nishiyama; Yuka Yamamoto; Kenji Kanenishi; Masami Ohno; Toshiyuki Hata; Yoshio Kushida; Reiji Haba; Motoomi Ohkawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-18       Impact factor: 9.236

View more
  6 in total

1.  Comments on characterization of solitary pulmonary nodules with 18F-FDG PET/CT relative activity distribution analysis.

Authors:  Orazio Schillaci; Ferdinando F Calabria
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

Review 2.  Competitive advantage of PET/MRI.

Authors:  Hossein Jadvar; Patrick M Colletti
Journal:  Eur J Radiol       Date:  2013-06-18       Impact factor: 3.528

3.  PET/MRI and PET/CT in advanced gynaecological tumours: initial experience and comparison.

Authors:  Marcelo A Queiroz; Rahel A Kubik-Huch; Nik Hauser; Bianka Freiwald-Chilla; Gustav von Schulthess; Johannes M Froehlich; Patrick Veit-Haibach
Journal:  Eur Radiol       Date:  2015-05-29       Impact factor: 5.315

Review 4.  Diagnostic performance of PET/CT and PET/MR in the management of ovarian carcinoma-a literature review.

Authors:  Mayur Virarkar; Dhakshinamoorthy Ganeshan; Anjalie Tara Gulati; Sarah Palmquist; Revathy Iyer; Priya Bhosale
Journal:  Abdom Radiol (NY)       Date:  2020-11-11

5.  Update on Diagnostic Performance of PET/MRI in Gynecological Malignancies: A Systematic Review and Meta-Analysis.

Authors:  Mayur Virarkar; Catherine Devine; Roland Bassett; Sanaz Javadi; Silvana De Castro Faria; Priya Bhosale
Journal:  J Belg Soc Radiol       Date:  2020-01-23       Impact factor: 1.894

6.  Diagnostic value of 18F-FDG PET/MRI for staging in patients with endometrial cancer.

Authors:  Hideaki Tsuyoshi; Tetsuya Tsujikawa; Shizuka Yamada; Hidehiko Okazawa; Yoshio Yoshida
Journal:  Cancer Imaging       Date:  2020-10-22       Impact factor: 3.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.